Compare Indinavir (Indinavir Sulfate) with Alternatives for HIV Treatment

Indinavir sulfate, sold under the brand name Crixivan, was once a game-changer in the fight against HIV. Introduced in the mid-1990s, it was one of the first protease inhibitors that helped turn HIV from a death sentence into a manageable condition. But times have changed. Today, Indinavir is rarely used in new patients - not because it doesn’t work, but because better options now exist. If you’re still on Indinavir or considering it, you deserve to know what’s out there now and why most doctors no longer recommend it.

What Indinavir Actually Does

Indinavir sulfate is a protease inhibitor. That means it blocks an enzyme HIV needs to copy itself. Without this enzyme, the virus can’t mature into infectious particles. When Indinavir was approved in 1996, it was used in combination with two other antiretrovirals - usually AZT and 3TC - forming what was called a triple therapy cocktail. This combo slashed viral loads and boosted CD4 counts in most patients.

But here’s the catch: Indinavir had strict rules. You had to take it on an empty stomach - at least one hour before or two hours after eating. Food could drop its absorption by up to 80%. Many people couldn’t stick to that schedule. It also caused kidney stones in about 10% of users, often requiring hospital visits. Nausea, diarrhea, and skin rashes were common. These side effects weren’t just inconvenient - they were dangerous.

Why Indinavir Fell Out of Favor

By the early 2000s, new drugs started appearing that worked just as well - or better - without the hassle. Darunavir, atazanavir, and lopinavir/ritonavir came along with fewer side effects, more flexible dosing, and better resistance profiles. Then came the integrase inhibitors: dolutegravir, bictegravir, and raltegravir. These drugs were simpler: one pill, once a day, with no food restrictions. They were also more forgiving if you missed a dose.

Studies from the U.S. CDC and European AIDS Clinical Society show that patients on newer regimens had higher rates of viral suppression and fewer treatment interruptions. Indinavir’s pill burden was high - often three or four pills a day. Newer drugs cut that to one or two. The difference wasn’t just convenience. It was survival. People who struggled with complex regimens were more likely to stop taking their meds - and that’s how drug resistance starts.

Top Alternatives to Indinavir Today

Here are the four most common alternatives used in 2025 - all approved by the FDA, WHO, and Australian Therapeutic Goods Administration:

• Dolutegravir (Tivicay): A once-daily integrase inhibitor. It’s effective against most HIV strains, including those resistant to older drugs. Side effects are mild - occasional headaches or insomnia. It’s safe in pregnancy and doesn’t interact badly with other meds.
• Bictegravir/tenofovir alafenamide/emtricitabine (Biktarvy): A single-pill regimen. No food restrictions. No drug interactions with statins, blood pressure meds, or antidepressants. Over 95% of patients maintain undetectable viral loads after one year.
• Darunavir/cobicistat (Prezcobix): A boosted protease inhibitor, similar to Indinavir but with better absorption and fewer kidney risks. Taken once daily with food. Still used in patients with resistance to newer drugs.
• Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya): Another single-pill option. Lowers kidney and bone toxicity compared to older tenofovir formulations.

These drugs don’t just outperform Indinavir - they make treatment feel normal. No more planning meals around pills. No more drinking gallons of water to avoid kidney stones. No more midnight trips to the ER.

Who Might Still Be on Indinavir?

If you’re still taking Indinavir, you’re likely one of two people:

1. You started treatment before 2005 and never switched because your viral load stayed under control.
2. You live in a region where newer drugs are expensive or hard to access.

In Australia, public health programs like the Pharmaceutical Benefits Scheme (PBS) cover Biktarvy, Tivicay, and Genvoya at low or no cost. Indinavir is no longer listed on the PBS - meaning patients pay full price, which can be over $1,000 per month. Most clinics stopped prescribing it by 2010. If you’re still on it, your doctor should have already discussed switching.

Staying on Indinavir isn’t necessarily dangerous - if you’ve been stable for years. But it’s outdated. Newer drugs have lower long-term risks: less kidney damage, less bone thinning, less fat redistribution. They’re also more effective at preventing transmission to partners. If you’re undetectable on Indinavir, you’re not infectious. But you’re still carrying more side effect risk than you need to.

Switching from Indinavir: What to Expect

Switching from Indinavir to a modern regimen is usually smooth. Most patients don’t notice much difference - except they feel better. Here’s what typically happens:

1. Your doctor runs a resistance test to check if your virus has mutations that might affect new drugs.
2. They check your kidney and liver function - Indinavir can cause subtle damage over time.
3. You’re switched to a single-pill regimen like Biktarvy or Tivicay.
4. You’re monitored for four to eight weeks to confirm the new drug is working.

Some people report mild nausea or dizziness for the first week - but it fades. The biggest change? No more fasting. You can eat breakfast with your pill. You can sleep through the night. You can travel without packing extra water bottles and snacks.

There’s one exception: if you’ve had multiple treatment failures and your virus is resistant to most drugs, your doctor might still consider a boosted protease inhibitor like darunavir. But even then, it’s not Indinavir.

Cost and Access: What You Need to Know

In Australia, the PBS subsidizes all first-line HIV treatments. Biktarvy, Tivicay, and Genvoya cost less than $30 per script for concession card holders - and free for others. Indinavir isn’t subsidized, so you’d pay over $1,000 monthly. That’s not just expensive - it’s unsustainable.

In lower-income countries, older drugs like Indinavir are sometimes still used because they’re cheaper to manufacture. But even there, generic versions of dolutegravir and raltegravir are now available for under $50 a year. The global shift away from Indinavir isn’t just clinical - it’s economic.

What You Should Do Now

If you’re taking Indinavir:

• Ask your doctor if you’re eligible to switch to a modern regimen.
• Request a resistance test if you haven’t had one in the last two years.
• Check your kidney function - a simple urine test can catch early signs of damage.
• Don’t stop Indinavir on your own. Stopping abruptly can cause rebound viral load and resistance.

If you’re newly diagnosed: Don’t even consider Indinavir. It’s not recommended by any major guideline in 2025. Ask for Biktarvy, Tivicay, or Genvoya. They’re safer, simpler, and more effective.

Final Thoughts

Indinavir was important. It saved lives. But medicine doesn’t stand still. What was cutting-edge in 1996 is now a relic. The goal today isn’t just to suppress the virus - it’s to live well, without side effects, without restrictions, without fear.

If you’re still on Indinavir, you’re not alone. But you don’t have to stay there. Talk to your doctor. Ask for an alternative. The options are better than ever - and they’re covered.